Beta amyloid deposition is not associated with cognitive impairment in Parkinson's disease

Simple item page
dc.contributor.authorMelzer TR
dc.contributor.authorStark MR
dc.contributor.authorKeenan RJ
dc.contributor.authorMyall DJ
dc.contributor.authorMacAskill MR
dc.contributor.authorPitcher TL
dc.contributor.authorLivingston L
dc.contributor.authorGrenfell S
dc.contributor.authorHorne KL
dc.contributor.authorYoung BN
dc.contributor.authorPascoe MJ
dc.contributor.authorAlmuqbel MM
dc.contributor.authorWang J
dc.contributor.authorMiller DH
dc.contributor.authorAnderson TJ
dc.contributor.authorMarsh, Steven
dc.contributor.authorDalrymple-Alford, John
dc.date.accessioned2021-07-05T02:06:06Z
dc.date.available2021-07-05T02:06:06Z
dc.date.issued2019en
dc.date.updated2021-06-29T03:26:29Z
dc.description.abstractThe extent to which Alzheimer neuropathology, particularly the accumulation of misfolded beta-amyloid, contributes to cognitive decline and dementia in Parkinson's disease (PD) is unresolved. Here, we used Florbetaben PET imaging to test for any association between cerebral amyloid deposition and cognitive impairment in PD, in a sample enriched for cases with mild cognitive impairment. This cross-sectional study used Movement Disorders Society level II criteria to classify 115 participants with PD as having normal cognition (PDN, n = 23), mild cognitive impairment (PD-MCI, n = 76), or dementia (PDD, n = 16). We acquired 18F-Florbetaben (FBB) amyloid PET and structural MRI. Amyloid deposition was assessed between the three cognitive groups, and also across the whole sample using continuous measures of both global cognitive status and average performance in memory domain tests. Outcomes were cortical FBB uptake, expressed in centiloids and as standardized uptake value ratios (SUVR) using the Centiloid Project whole cerebellum region as a reference, and regional SUVR measurements. FBB binding was higher in PDD, but this difference did not survive adjustment for the older age of the PDD group. We established a suitable centiloid cut-off for amyloid positivity in Parkinson's disease (31.3), but there was no association of FBB binding with global cognitive or memory scores. The failure to find an association between PET amyloid deposition and cognitive impairment in a moderately large sample, particularly given that it was enriched with PD-MCI patients at risk of dementia, suggests that amyloid pathology is not the primary driver of cognitive impairment and dementia in most patients with PD.en
dc.identifier.citationMelzer TR, Stark MR, Keenan RJ, Myall DJ, MacAskill MR, Pitcher TL, Livingston L, Grenfell S, Horne KL, Young BN, Pascoe MJ, Almuqbel MM, Wang J, Marsh SH, Miller DH, Dalrymple-Alford JC, Anderson TJ (2019). Beta amyloid deposition is not associated with cognitive impairment in Parkinson's disease. Frontiers in Neurology. 10(APR). 391-.en
dc.identifier.doihttp://doi.org/10.3389/fneur.2019.00391
dc.identifier.issn1664-2295
dc.identifier.urihttps://hdl.handle.net/10092/102174
dc.languageeng
dc.language.isoen
dc.publisherFrontiers Media SAen
dc.rightsCopyright © 2019 Melzer, Stark, Keenan, Myall, MacAskill, Pitcher, Livingston, Grenfell, Horne, Young, Pascoe, Almuqbel, Wang, Marsh, Miller, Dalrymple- Alford and Anderson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en
dc.rights.urihttp://hdl.handle.net/10092/17651en
dc.subjectParkinson's diseaseen
dc.subjectamyloid PETen
dc.subjectFlorbetabenen
dc.subjectdementiaen
dc.subjectcentiloiden
dc.subjectmild cognitive impairmenten
dc.subject.anzsrc1103 Clinical Sciencesen
dc.subject.anzsrc1109 Neurosciencesen
dc.subject.anzsrc1701 Psychologyen
dc.subject.anzsrcFields of Research::32 - Biomedical and clinical sciences::3209 - Neurosciences::320905 - Neurology and neuromuscular diseasesen
dc.subject.anzsrcFields of Research::32 - Biomedical and clinical sciences::3202 - Clinical sciences::320206 - Diagnostic radiographyen
dc.subject.anzsrcFields of Research::52 - Psychology::5202 - Biological psychology::520203 - Cognitive neuroscienceen
dc.subject.anzsrcFields of Research::52 - Psychology::5202 - Biological psychology::520206 - Psychophysiologyen
dc.titleBeta amyloid deposition is not associated with cognitive impairment in Parkinson's diseaseen
dc.typeJournal Articleen
uc.collegeFaculty of Science
uc.departmentSchool of Physical & Chemical Sciences
uc.departmentSchool of Psychology, Speech and Hearing
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinsons Disease.pdf
Size:
1.28 MB
Format:
Adobe Portable Document Format
Download
Collections
Science: Journal Articles